Vir Biotechnology, Inc. VIR will issue more than 7.14 million shares between $20 and $22 Friday on the Nasdaq. The offering represents 6.5% of outstanding shares and is expected to raise about $180.7 million. The California-based company develops candidates to treat hepatitis B, HIV, influenza and tuberculosis.